Next Article in Journal
Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
Next Article in Special Issue
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
Previous Article in Journal
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Previous Article in Special Issue
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
 
 
Article

Article Versions Notes

Cancers 2022, 14(3), 649; https://doi.org/10.3390/cancers14030649
Action Date Notes Link
article xml file uploaded 27 January 2022 13:37 CET Original file -
article xml uploaded. 27 January 2022 13:37 CET Update https://www.mdpi.com/2072-6694/14/3/649/xml
article pdf uploaded. 27 January 2022 13:38 CET Version of Record https://www.mdpi.com/2072-6694/14/3/649/pdf
article html file updated 27 January 2022 13:39 CET Original file -
article html file updated 31 July 2022 06:51 CEST Update https://www.mdpi.com/2072-6694/14/3/649/html
Back to TopTop